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Abstract
Cancer-related psychological distress may lead to depression and anxiety among sur-
vivors. The vast majority of patients with Hodgkin lymphoma (HL) become long-term 
survivors, but the risk of mental health problems after HL is not well-characterized. 
Using national population-based registries, we investigated the cumulative incidence 
of psychotropic drug (antidepressants, antipsychotics, and anxiolytics) use (proxies 
for depression and anxiety) in HL patients as well as if an increased risk would nor-
malize over time for patients in remission. The study included 945 HL patients aged 
18-92 years and 4725 matched persons. In total, 215 HL patients (22.8%) received 
a prescription of any psychotropic drug (PD) at some point after date of diagnosis 
compared to 545 persons (11.5%) in the matched cohort. Cumulative incidences with 
death/relapse as competing risk confirmed that HL patients were at higher risk of re-
ceiving psychotropic drug prescriptions, but the increased risk was transient and nor-
malized to the matched population 5 years into survivorship. Increased age, Eastern 
Cooperative Oncology Group performance status, and disease stage were associated 
with higher risk of psychotropic drug prescriptions. Given the increased rate of psy-
chotropic drug prescriptions after HL diagnosis, screening for symptoms of depres-
sion and anxiety is warranted after HL diagnosis and first years into survivorship.
K E Y W O R D S
anxiety, depression, epidemiology, Hodgkin lymphoma, psychotropic drugs
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1 |  INTRODUCTION
Cancer-related psychological distress is well described, and 
several studies have consistently found increased risk of depres-
sion and anxiety among cancer patients as compared to persons 
without cancer, which can lead to increased use of psychotropic 
drugs (PDs) in patients with cancer.1-9 Poor mental health, and, 
in particular, unrecognized depression and anxiety could sub-
stantially reduce quality of life in patients surviving cancer and 
might even increase mortality.10,11 Depression and anxiety may 
also have detrimental impact on socioeconomic outcomes due 
to prolonged sick leave, increased risk of disability pension, and 
difficulties in maintaining family life.12-15 Thus, attention to the 
mental health problems is important to ensure good quality of 
life following a cancer diagnosis.
In general, female sex and higher age are both associated 
with higher lifetime risk of depression and anxiety in the gen-
eral population.5-6,16,17 However, in patients surviving cancer, 
the risk of depression and anxiety is dependent on the type of 
cancer, that is, incidence of depression and anxiety is higher 
in patients with gynecological or lung cancer compared to pa-
tients with prostate or skin cancer, possibly reflecting the more 
favorable outcomes of the latter two.6,17 Research focusing in 
particular on occurrence of depression and anxiety following 
hematological cancers is limited.6,18-21
Hodgkin lymphoma (HL) is a rare, B cell-derived malig-
nancy characterized by an incidence peak in younger adults of 
age 18-30 years and a second incidence peak after the age of 
50 years.22-24 Contemporary combined modality treatments of 
HL result in a 5-year survival rate of 87.6%.24,25 Universally 
high survival rates, regardless of disease stage, in patients tol-
erating multiagent chemotherapy regimens warrant research 
in HL survivorship with delineation of potential health issues 
faced by patients. To study the risk of mental health problems 
after diagnosis of HL, we compared the cumulative incidence 
of depression and anxiety among the Danish patients with 
HL and the matched population using prescription of PDs 
(antidepressants, anxiolytics, and antipsychotics) as proxies 
for depression and anxiety. Secondly, we investigated the 
patterns of PD prescriptions by time elapsed since diagnosis 
to analyze if a potential initial increase in PD prescriptions 
after diagnosis would return to rates as found in the matched 
population.
2 |  MATERIALS AND METHODS
2.1 | Data sources
All Danish residents are assigned a unique personal 10-digit 
Civil Personal Register (CPR) number at birth or immigration, 
which enables linkage of various population-based registries. 
The Danish Civil Registration System includes demographic 
information such as age, sex, marital status, citizenship, and mu-
nicipality of residence since 1960.26-28 The Danish Education 
Register, established in 1910, holds information on educational 
level of Danish citizen.29 The Danish National Patient Registry 
includes data for all inpatient-, outpatient-, and emergency de-
partment contacts in Danish hospitals since 1977 and uses ICD-
10 for coding diagnoses.30 The National Prescription Registry 
holds data on all claimed prescription from Danish pharmacies 
since 1994 (complete since 1995). The registry uses the global 
Anatomical Therapeutic Chemical classification (ATC) code 
for identifying drugs.31,32 In this study, any prescription of an-
tidepressants (ATC - N06A), antipsychotics (ATC - N05A), 
and anxiolytics (ATC - N05B) were used as proxies for depres-
sion and anxiety. The Danish Lymphoma Registry (LYFO) 
is a nationwide registry containing information on lymphoma 
patients diagnosed and treated at departments of hematology 
in Denmark. The coverage of LYFO is 94.9%. Data include 
detailed disease-related information (lymphoma subtype, stage, 
risk category, sites of involvement, etc), treatment information, 
and outcomes. Data completeness and accuracy are high with 
completeness ranging between 92% and 100% and positive pre-
dictive values ranging between 87% and 100%.33
2.2 | Study population
A cohort of patients with HL diagnosed with both classical 
and lymphocyte-predominant HL between 01 January 2005 
and 31 December 2015 aged ≥18 years was identified using 
LYFO. Patients with fictive CPR number (foreign citizens) and 
patients diagnosed prior to immigration to Denmark were ex-
cluded as follow-up was not available. Date of HL diagnosis 
was set as inclusion date, in the following referred to as the 
index date. Patients who received a prescription of PDs within 
10 years prior to the index date were excluded in order to de-
scribe the incident use of PDs. For each patient with HL, five 
random persons from the Danish population were matched on 
year and month of birth and sex and included in a control co-
hort (background population). Inclusion date for the matched 
persons was the index date of the index patient. Furthermore, 
matched persons had to be alive and living in Denmark at the 
index date with no prescriptions of PDs within 10 years prior to 
that date. Matched persons later being diagnosed with HL were 
censored at the time of HL diagnosis. All included in the final 
study population where followed until event (first PD prescrip-
tion), death, or censored at the end of follow-up, emigration out 
of Denmark, or reported missing.
2.3 | Statistical analysis
Baseline characteristics at time of inclusion were described 
by proportions for categorical variables, while continuous 
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variables were described by medians with interquartile 
ranges, summarized separately for patients and the back-
ground population. Difference between baseline characteris-
tics in HL patients as compared to the matched background 
population where described using Pearson's Chi-square test, 
Fischer's exact test, and Mann-Whitney U test. Time to first 
PD prescription was computed for patients and the matched 
population and presented using cumulated incidence curves. 
Furthermore, 5-year cumulative incidences were computed 
using the Aalen-Johansen estimator with deaths, relapses, 
or a matched person being diagnosed with HL before PD 
prescription treated as competing risk, and presented by a 
forest plot (with 95% confidence intervals (CIs)) for HL 
patients stratified on gender, age, Ann Arbor stage, Eastern 
Cooperative Oncology Group (ECOG) performance status, 
Charlson Comorbidity Index (CCI), treatment regimen, and 
educational level. Significant difference between the pa-
tient's and the matched population's cumulative incidence 
was tested using Gray's test.34 The pseudo-observation 
method was used to compute 5-year cumulative incidences 
at various time points after diagnosis to estimate differences 
in PD prescriptions over time.35,36 In order to do so, all pa-
tients with HL alive at 1-, 2-, and 5  years after the index 
date without any PD prescriptions were rematched to five 
random persons from the matched population using the same 
procedure as previously described. Pseudo-observations for 
cumulative incidences regarding both HL patients and the 
matched cohort were computed. Association between groups 
and outcomes (PD prescriptions) was further evaluated using 
an adjusted Cox proportional hazards regression analysis. 
Variables for adjustment were chosen before analysis ac-
cording to clinical relevance and known prognostic impor-
tance including age, sex, and educational level. Hazard ratios 
(HRs) were calculated. Throughout the study, 95% CIs were 
reported and used as level of statistically significant.
Statistical analyses were conducted using SAS version 9.4 
(SAS Institute Inc) and RStudio version 1.1.447 (RStudio, 
Inc) and R version 3.6.1 (R foundation for Statistical 
Computing).
All analysis was performed on pseudo-anonymized data 
using the secured network governed by Statistics Denmark. 
The study was approved by the Danish Data Protection 
Agency.
3 |  RESULTS
3.1 | Baseline characteristics
We identified 945 patients with HL who fulfilled the inclu-
sion criteria. Median age was 39 years and the male:female 
ratio was 1.7. Median follow-up was 7.2 (7.0-7.4) years 
for HL patients (reverse Kaplan-Meier method). Included 
patients with HL were matched to 4725 persons from the 
background population Table 1 shows baseline information 
for both patients with HL and the background population 
including age, disease stage, CCI score, and ECOG perfor-
mance status. A statistically significant difference (P-value 
<.05) between HL patients and the background population 
was found for CCI score, educational level, and PD use (both 
overall and stratified on PD type).
3.2 | Incident PD use
In total, 215 (22.8%) of the patients with HL received at least 
one prescription for any PD compared to 384 (11.5%) within 
the background population (Table 1). Antidepressants were 
the most frequent prescribed PD type (16.3% for patients 
with HL and 8.6% for background population). If including 
hypnotics and sedatives (ATC – N05C) as anxiolytics (due to 
the benzodiazepine-like nature of hypnotics and sedatives), 
anxiolytics would be the far most prescribed PD in patients 
with HL (23.9% compared to 10.0% in the background popu-
lation; data not presented).
Figure 1 shows the cumulative incidences of time to first 
PD prescription stratified by type of PD. Patients with HL had 
higher cumulative incidence of PD prescriptions compared 
to the background population, which was also illustrated 
in a crude Cox regression analysis (HR 2.63; CI 2.24-3.08; 
P < .001; Table 2).
A sensitivity analysis was performed, in which incident 
PD use was defined as having received at least two prescrip-
tions of PDs. The 5-year cumulative incidence is presented 
in Figure S1. Results of the sensitivity analysis are consistent 
with the primary analysis results.
An additional analysis, in which the cumulative incidence 
of time to first PD prescription from 5 years prior to index 
date till 5  years after the index date was performed to in-
vestigate from which time point the use of PDs among HL 
patients departed from the use in the matched background 
population. This analysis did not exclude HL patients with 
PD prescriptions prior to HL diagnosis. The cumulative in-
cidence (Figure S2) among HL patients gradually departed 
from the use of PDs in the background population already 
2 years prior to index date and strongly increased in the year 
prior to diagnosis.
3.3 | Incident PD use in relapsed 
HL patients
In total, 117 HL patients (12.4%) experienced relapse during 
follow-up. To address the use of PDs in relapsed HL patients, 
patients with relapsed HL and without PD use 6  months 
prior to the relapse date were rematched to the background 
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T A B L E  1  Baseline characteristics and psychotropic drug use in patients with HL and the background population
 
Patients with 
HL (n = 945)
Background population 
(n = 4725) P-value
Age, n (%)
Median (IQR) 39 (27-59) 39 (27-59) 1.000
18- to 30-year-old 288 (30.5%) 1440 (30.5%) 1.000
31- to 60-year-old 407 (43.1%) 2035 (43.1%)  
61-year-old 250 (26.5%) 1250 (26.5%)  
Sex, n (%)
Male 591 (62.5%) 2955 (62.5%) 1.000
Female 354 (37.5%) 1770 (37.5%)  
CCI score prior to diagnosis, n (%)
0 771 (81.6%) 4189 (88.7%) <.001*
≥1 174 (18.4%) 536 (11.3%)  
Ann Arbor stage, n (%)
Limited stage (I-II) 517 (54.7%) NA NA
Advanced stage (III-IV) 424 (44.9%) NA  
ECOG performance status, n (%)
0 670 (70.9%) NA NA
1-4 271 (28.7%) NA  
Treatment
2-4 cycles ABVD 312 (33.0%) NA NA
6-8 cycles ABVD 375 (39.7%) NA  
6-8 cycles BEACOPP 94 (9.9%) NA  
Other 91 (9.6%) NA  
Missing 73 (7.7%) NA  
Educational level (ISCED), n (%)
Primary education 399 (42.2%) 1597 (33.8%) <.001*
Secondary/tertiary education 500 (52.9%) 2210 (46.8%)  
Missing 46 (4.9%) 918 (19.4%)  
Any psychotropic drug prescription overall, n (%)
Yes 215 (22.8%) 545 (11.5%) <.001*
No 730 (77.2%) 4180 (88.5%)  
Antidepressant prescription, n (%)
Yes 154 (16.3%) 404 (8.6%) <.001*
No 791 (83.7%) 4321 (91.4%)  
Antipsychotic prescription, n (%)
Yes 37 (3.9%) 129 (2.7%) .011*
No 908 (96.1%) 4596 (97.3%)  
Anxiolytic prescription, n (%)
Yes 93 (9.8%) 189 (4.0%) <.001*
No 852 (90.2%) 4536 (96.0%)  
Days between first and last psychotropic drug prescription, median (IQR) 113 (0-888) 208 (0-1018) .358
Days between first and last antidepressant prescription, median (IQR) 157.5 (0-701) 312.5 (1.5-1055.75) .204
Days between first and last antipsychotic prescription, median (IQR) 0 (0-255) 50 (0-672) .069
Days between first and last anxiolytic prescription, median (IQR) 0 (0-330) 0 (0-99) .141
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, vincristine, procarbazine, and 
prednisone; CCI, Charlson Comorbidity Index; ECOG, Eastern Cooperative Oncology Group; HL, Hodgkin lymphoma; IQR, interquartile range; ISCED, International 
Standard Classification of Education.
*Statistical significant (P-value <.05). 
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population with new index date being the date of relapse. 
The 5-year cumulative incidence with death without PD pre-
scription as competing risk is presented in Figure S3, which 
shows an overall higher use of PDs in relapsed HL patients 
at 5 years after relapse date (27.1%) compared to the back-
ground population (7.7%) as well as a higher use of antide-
pressants (18.8% vs 5.7%), antipsychotics (6.0% vs 1.5%), 
and anxiolytics (12.8% vs 2.4%).
3.4 | Association between PD, patients’ 
characteristics, and clinicopathologic features
The 5-year cumulative incidences of PD prescriptions strat-
ified on the type of PD in the matched cohort (Figure  S4) 
showed that age >60  years, females, and CCI score ≥1 
all were associated with higher rates of PD prescriptions. 
Educational level did not show any difference in the back-
ground population. Figure  2 shows stratified 5-year cumu-
lative incidences among HL patients according to age, sex, 
disease stage, ECOG performance status, CCI, and educa-
tion. Age >30  years, advanced stage disease, and ECOG 
performance status >1 at diagnosis were all associated with 
higher rates of PD prescriptions. The associations were 
mainly driven by the use of antidepressants.
Crude Cox regression analysis for the association between 
clinical features and PD prescriptions among HL patients is 
presented in Table 2. Age (HR 1.69; CI 1.19-2.40 in 31- to 
60-year-old and HR 2.57; CI 1.77-3.75 in ≥61-year-old with 
age 18-30 years as reference), ECOG performance status ≥1 
(HR 2.19; CI 1.66-2.89), advanced stage disease (HR 1.84; 
CI 1.41-2.41), CCI score ≥1 (HR 1.53, CI 1.10-2.12), and 
treatment with 6-8 cycles of ABVD (doxorubicin, bleomycin, 
vincristine, and dacarbazine) (HR, 1.45; CI 1.05-2.00) were 
all significantly associated with PD prescriptions, whereas 
sex and educational level were not associated with the use 
of PDs.
3.5 | Time to normalization of PD 
prescriptions
Differences in cumulative incidences of PD prescriptions be-
tween HL patients and the background population computed 
from 1-, 2-, and 5 years after the index date are presented in 
Figure 3. The differences gradually diminished as time elapsed 
and 5 years after diagnosis, patients with HL had similar rate 
of incident PD prescriptions as the background population.
4 |  DISCUSSION
This nationwide study demonstrates that 5-year cumulative 
incidence of PD prescriptions was increased among patients 
with HL (21.5%) compared to the background population 
(8.4%). These data support results from other studies show-
ing higher risk of depression and anxiety in patients with 
cancer.1,4-9 Risk factors for PD prescription were increasing 
age, advanced disease stage, CCI score ≥1, poor ECOG per-
formance status (≥1), and patients treated with 6-8 cycles of 
ABVD. However, treatments differ in length, why interpreta-
tion of the results must be careful. Importantly, the increased 
risk of mental health problems leading to PD prescriptions 
appears to be transient as cumulative incidence of PD pre-
scriptions among HL patients surviving the initial 5  years 
after diagnosis without receiving PD prescriptions becomes 
F I G U R E  1  Cumulative incidence 
curves of time to first prescription of 
psychotropic drugs (PDs) (antidepressants, 
antipsychotics, anxiolytics) and time to the 
first of any PD for all patients stratified on 
patients with HL and the matched cohort. 
Gray's test showed significant difference 
between cumulated incidences for HL 
patients and the background population 
regarding all four cumulated incidence 
curves (described in figure legends)
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similar to that of a matched background population. Most in-
terestingly, Figure S2 showed that the cumulative incidence 
of first PD prescription was higher for HL patients already 
from 2 years prior to index date. To our knowledge, PDs have 
not been shown as a risk for developing HL. Furthermore, 
Figure S2 showed a rapidly increasing cumulative incidence 
during the months prior to the index date. The reason may 
be that insidious HL symptoms, such as fatigue, weight loss, 
and night sweats (B-symptoms), could initially be misinter-
preted as mental health problems such as stress or depression. 
Additionally, the present study shows that HL patients with 
relapse have markedly higher 5-year cumulative incidence 
(27.1%) than that of the background population (7.7%), as 
well as the overall population of HL population (22.8%), 
which might be explained by the more stressful situation with 
higher degree of uncertainty faced by relapsed HL patients.
In a previous study by Linden et al,6 a routine evaluation 
of mental health was carried out at British Columbia Cancer 
Agency centers by distributing questionnaires to patients 
with various types of cancers prior to treatment. In total, 
19% of 9394 patients had clinical anxiety according to the 
Psychosocial Screen for Cancer (PSSCAN),37 while 12.9% 
patients had clinical depression. In the subgroup with he-
matological cancers, the prevalence of anxiety was 38/167 
(22.8%) and the prevalence of depression was 28/166 (16.9%). 
Our results resemble those by Linden et al,6 although the au-
thors did not provide detailed data on mental health problems 
according to type of hematological cancer. As hematological 
cancers are highly diverse in terms of age at diagnosis, symp-
tomatic burden, treatments, and prognosis, some differences 
in risk of mental health problems would be expected.
Conte et al2 investigated the incident use of PDs in all sub-
types of non-Hodgkin B-cell lymphoma patients (B-NHL) 
from date of diagnosis and 8 months onward in France. In total, 
745 incident B-NHL patients with a mean age of 65.1 years 
were included. In this study, 31.5% of the patients had at least 
one prescription for a PD, after a median time from diagnosis 
of approximately 2 months, and younger age was associated 
with higher PD use. The proportion of patients receiving PDs 
was markedly higher than in our study. Our results regarding 
age are reciprocal to the results of Conte et al,2 as higher age 
in patients with HL was associated with higher cumulative in-
cidence of PD prescriptions. The difference might be caused 
by the significant difference in prognostic outcomes between 
B-NHL and HL patients. B-NHL has lower expected 5-year 
survival combined with high risk of relapse as compared to 
HL across all ages. Hereby, older B-NHL patients are more 
likely to die before having the opportunity for receiving a PD 
prescription. Also, as young B-NHL patients have both lower 
cure rates and higher risk of relapse as compared to young 
HL patients, the risk of affected mental health may be higher 
in B-NHL patients given the worse prognostic outcomes.
The psychological health measured by fatigue level, 
physical functioning, social functioning, cognitive prob-
lems, and quality of life has been assessed in HL survivors 
in other studies.38-39,41,42 Hjermstad et al38 showed a higher 
prevalence of chronic fatigue in HL survivors compared to 
a Norwegian normative population (30% vs 11%). These 
findings have been confirmed by Loge & Kaasa20 and 
T A B L E  2  Association between use of psychotropic drugs in HL 
and clinical variables
  HR 95% CI P-value
Patients with HL vs background population
Controls 1.00 (reference)  
Cases 2.63 2.24-3.08 <.001*
Sexa 
Male 1.00 (reference)  
Female 1.21 0.93-1.59 .163
Age-groupa 
18- to 30-year-old 1.00 (reference)  
31- to 60-year-old 1.69 1.19-2.40 .004*
≥61-year-old 2.57 1.77-3.75 .007*
ECOG performance statusa 
0 1.00 (reference)  
≥1 2.19 1.66-2.89 <.001*
Ann Arbor Stagea 
Limited stage 
(I-II)
1.00 (reference)  
Advanced stage 
(III-IV)
1.84 1.41-2.41 <.001*
CCI-scorea 
0 1.00 (reference)  
≥1 1.53 1.10-2.12 .011*
Treatmenta 
2-4 cycles ABVD 1.00 (reference)  
6-8 cycles ABVD 1.45 1.05-2.00 .024*
6-8 cycles 
BEACOPP
0.95 0.56-1.61 .857
Other 1.83 1.15-2.92 .011*
Missing 1.49 1.15-2.92 .166
Educational level (ISCED)a 
Primary education 1.00 (reference)  
Secondary/tertiary 
education
1.11 0.84-1.46 .466
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; 
BEACOPP, bleomycin, etoposide, doxorubicin, vincristine, procarbazine, and 
prednisone; CCI, Charlson Comorbidity Index; CI, confidence interval; ECOG, 
Eastern Cooperative Oncology Group; HL, Hodgkin lymphoma; HR, hazard 
ratio; IQR, interquartile range; ISCED, International standard classification of 
education.
aOnly HL patients are included in Cox regression analysis. 
*Statistically significant (P-value <.05). 
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Daniëls et al18 in which Daniëls et al18 found an associa-
tion between chronic fatigue and depression/anxiety in HL 
patients. Furthermore, systematic reviews by [39,41,42] 
investigated the impact of health-related quality of life in 
HL survivors and cancer-related fatigue. The authors found 
that HL survivors were more likely to report problems with 
physical, social, and cognitive functioning, general health, 
and fatigue, whereas problems directly related to mental 
health was not different from the background population. 
As more self-reported general and psychological health 
problems have been shown among HL patients along with 
an increased incidence of depression and anxiety, a few 
studies looked into the risk of committing suicide in HL 
patients relative to the European general population.43,44 
Both studies showed a higher suicidal risk in HL patients, 
and 43 identified male HL patients as having higher risk of 
suicide than female HL patients. However, suicide is a rare 
cause of death in Denmark, why analysis on this matter 
could not be performed (total number of suicides for both 
HL patients and the matched background population ≤3).
A strength of this study is the use of high-quality nationwide 
population-based registries characterized by high coverage 
ensuring all HL patients eligible for inclusion were analyzed. 
This minimizes the risk of selection bias and ensures near to 
complete follow-up of all patients. Among important limita-
tions of the study are the reliance on PD prescription data 
as proxies for depression and anxiety. National guidelines for 
treatment of depression states that pharmacological treatment 
should only be initiated if severity of depression is moderate 
or severe, while psychotherapy or psychoeducation should be 
initiated at all grades of depression severity.45 As we used PD 
prescriptions as proxies for depression and anxiety, we would 
only include patients with moderate or severe depressions ac-
cording to the National guidelines regarding pharmacologi-
cal treatment of depression. However, this bias exists in both 
the patient cohort as well as the background population and 
may have less impact on estimate differences in cumulative 
incidence rates. On contrary, as HL patients would be seen 
by doctors more often than the average Danish citizen during 
both the treatment and the follow-up program, surveillance 
bias may be introduced. Secondly, we did not account for the 
amount of prescriptions received. Hereby, patients only re-
ceiving one prescription of, that is, antidepressants would be 
defined as having depression, even though one prescription 
would not be enough for treating depression of any severity. 
However, a sensitivity analysis defining PD use as having 
F I G U R E  2  Forest plot showing 
5-year cumulative incidences provided 
with 95% confidence intervals of use of 
psychotropic drugs (PDs) for clinical 
variables in patients with Hodgkin 
lymphoma (HL) stratified on type of PD
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had at least two PD prescriptions did not alter the conclusion. 
Instead of clinical depression, patients might suffer from ad-
justment disorders which have symptoms similar to major de-
pression disorder. Hence, HL patients may have received PD 
prescriptions due to adjustment disorder and overt depression. 
This could be supported by the fact that the median number 
of days between the first and last prescription of antidepres-
sants was shorter among HL patients (113 days, IQR 0-888, 
Table 1) compared to the matched cohort (208 days, IQR 1.5-
1018, Table 1). This is supported in a meta-analysis showing 
that adjustment disorders are highly prevalent in both onco-
logical and hematological care settings with a prevalence of 
19.4% during the first 5 years after diagnosis.7 Thirdly, the 
Danish Prescription Registry does not contain information 
regarding the clinical indications for the prescriptions. As 
PDs are widely used for other purposes, that is analgesics in 
neuropathic pain management, this might result in an overes-
timation of depression and anxiety, although studies indicate 
a low incidence of both neuropathy and neuropathic pain.47-49
In conclusion, the present study showed a higher cumu-
lative incidence of PD prescriptions among HL patients, 
which likely indicates a higher incidence of mental health 
problems possibly due to depression and anxiety triggered by 
the stressful situation. Therefore, focus on the mental health 
in HL patients is important from a clinically perspective, 
but according to the findings of this study, this is relevant 
mainly during the initial years after diagnosis where risk is 
significantly higher than that of the background population. 
To firmly address the specifics of mental health problems 
in HL patients, prospective studies using validated screen-
ing procedures for psychiatric disorders in cancer patients 
(ie, Major Depression Inventory (MDI) questionnaire, 
Patient Health Questionnaire (PHQ), Hospital Anxiety 
and Depression Scale (HADS), and Generalized Anxiety 
Disorder (GAD-2) scale50,51) are warranted and the effects 
of different interventions, including pharmacological treat-
ment and psychological support, need to be established to 
provide HL patients with the best possible support.
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